Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics Corp. has reported promising results from its ongoing ABILITY-1 study, showing significant efficacy of its MDNA11 treatment in combination with KEYTRUDA for challenging cancer types. The study highlights potential breakthroughs in treating cancers typically resistant to immunotherapy, with a 70-year-old patient achieving a complete response and demonstrating the potential of MDNA11 to enhance existing treatments.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Oppenheimer Pounds the Table on Coinbase Stock
- New “Anti-Woke” ETF Targets Starbucks (NASDAQ:SBUX)
- Ford (NYSE:F) Plans New EV Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
